Drug Trial Radar · NCT06617429
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
129
Actual
Start
Dec 3, 2024
Primary completion
Jul 10, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
Conditions
- Angelman Syndrome
Interventions
GTX-102Drug
antisense oligonucleotide
Sham-LPProcedure
Small needle prick on the lower back at the location where the LP injection is normally made
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Bayley-4 Cognitive Raw Score Without Caregiver Input at Day 338Time frame: Baseline, Day 338
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
Cedars Sinai
Los Angeles, California
UCSD, Rady Children's Hospital
San Diego, California
UCSF
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Nicklaus Children's Hospital
Miami, Florida
Rare Disease Research
Atlanta, Georgia
Rush University
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Children's Mercy
Kansas City, Missouri
Columbia University Medical Center
New York, New York
UNC Chapel Hill Pediatrics
Chapel Hill, North Carolina
Rare Disease Research
Hillsborough, North Carolina
The University of Texas
Austin, Texas
Carum Research Inc
Dallas, Texas
British Columbia Children's Hospital
Vancouver, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
University of Leipzig
Leipzig, Germany
Haunersche Kinderklinik
Munich, Germany
Osaka City General Hospital
Osaka, Japan
Hokkaido University Hospital
Sapporo, Japan
Nagoya City University Graduate School of Medical Sciences
Nagoya, Aichi-ken, Japan
Medical University of Gdańsk
Gdansk, Poland
Polish Mothers Memorial Institute
Lodz, Poland
Hospital Universitario Parc Tauli
Barcelona, Spain
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.